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CC BY-NC-ND license (http://creativSummary Background: Prostate cancer (PCa) is a leading cause of cancer-related death in
men, which emphasizes the need for novel therapeutic approaches. Targeting microRNA (miR-
NA) has been considered as a therapeutic strategy against cancers. Human miR-204-5p poten-
tially targeting BCL2 has been reported to be downregulated in various cancers. We
hypothesized that miR-204-5p overexpression induces cancer cell apoptosis by repressing
BCL2 expression.
Methods: A vector harboring mature miR-204-5p was constructed and delivered into human
PCa cells. The expression level of miR-204-5p was determined by miRNA quantitative polymer-
ase chain reaction (QPCR). Luciferase reporter assays were performed to verify the function of
mature miR-204-5p and its direct binding to BCL2 transcripts. The expression levels of BCL-2
messenger RNA (mRNA) and protein samples were measured by QPCR and Western blot,
respectively. Cell viability was detected by WST-1 assays. Induction of apoptosis was deter-
mined by increased levels of cleavage caspase 3 and caspase 3/7 activity.
Results: The expression levels of miR-204-5p were downregulated in PCa cells compared with
normal prostate epithelial cells. Transfection of pSM-204 resulted in up to 6.2-fold higher
expression of miR-204-5p when compared with pSM control. The mRNA levels of several poten-
tial target genes of miR-204-5p were decreased in pSM-204-transfected PC3 and Rv1 cells. BCL2
mRNA and protein expression decreased in miR-204-5p-transfected cells, which led to cyto-
chrome C release from mitochondria. It subsequently increased cleaved caspase 3 and caspaseeclare no conflicts of interest.
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cancer cells, Asian Journal of Surger3/7 activities and reduced cell viability. Cotransfection of a reporter vector harboring the BCL2
30-untranslated region to compete with endogenous transcripts partially rescued miR-204-5p-
induced apoptosis.
Conclusion: Human miR-204-5p targets BCL2 in PCa cells. Restoration of miR-204-5p in PCa
could therefore be considered as a novel strategy by targeting antiapoptotic BCL2.
Copyright ª 2016, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
The incidence and mortality of prostate cancer (PCa) in
Asian populations have rapidly increased. It has become
the sixth common cancer in Taiwan since 1996.1 The age-
adjusted incidence rate of PCa was reported to have
increased 18-fold in 2012 compared with that in 1985.2
Therefore, exploring the mechanisms of the initiation
and progression of PCa may contribute to optimize the
therapeutic strategies. Deregulation of epigenetic
mechanism has been investigated as a relevant driving
force in PCa over the past decades.3 More recently, the
expression of deregulated microRNAs (miRNAs) in PCa was
revealed.4,5
miRNAs are approximately 22-nt long noncoding RNAs
transcribed endogenously, which are involved in a new
level of gene regulation. miRNAs play a role in gene
regulation by cleaving or repressing the translation of their
target messenger RNA (mRNAs) at the post-transcriptional
level. Unlike transcriptional factors promoting gene ex-
pressions, miRNAs are recognized as negative regulators,
which bind to their target mRNAs and suppress protein
translation by either blocking translation or destabilizing
mRNA.6 miRNAs have been reported to be involved in many
important biological functions. For example, miR-15a and
miR-16 induce apoptosis by targeting BCL2; miR-375 is a
pancreatic-specific miRNA that regulates insulin secre-
tion.7,8 Furthermore, high-throughput techniques such as
microarray analysis revealed aberrant miRNA expression in
numerous tumors compared with their normal counter-
parts, suggesting that there exists a link between miRNAs
and cancer.9
In tumor cells, expression of miR-204-5p has been re-
ported to be downregulated in several types of tumors.10,11
The downregulation was suggested to contribute to tumor
growth through the repression of miR-204-5p targets
including HOXA10 and MEIS1, as well as some predicted
targets such as BCL2.12,13 miR-204-5p is located on chro-
mosome 9q21.qq within an intron of TRPM3, a gene that is
downregulated in bladder cancer.14 However, the biological
functions of miR-204-5p and the genes it regulates are still
unclear.
To gain insight into the biological roles of miR-204-5p,
we analyzed the predicted targets of miR-204-5p and
identified a well-known antiapoptotic genedBCL2. In this
study, we evaluated the direct interaction between miR-
204-5p and BCL2, detected BCL2 suppression, and
measured the induced apoptosis in PCa cells with elevated
miR-204-5p expression.in Y-C, et al., Tumor suppressor
y (2016), http://dx.doi.org/10.102. Methods
2.1. Construction of miRNA expression plasmids
Paired oligonucleotides consisting of mature miR-204-5p se-
quences were annealed and cloned into a small-RNA
expression vector, pSM, as described previously.15 This clon-
ing step generated pSM-204 that expresses maturedmiR-204-
5p. We also constructed two other miRNA expression vectors
that expressed miR-15a and miR-214 as positive and negative
controls,7 namely, pSM-15 and pSM-214, respectively. The
oligonucleotides used in this study are listed in Table 1.
2.2. Cell culture
Human PCa cell lines including PC3 (CRL-1435), CWR22Rv1
(Rv1, CRL-2505), and LNCaP (CRL-1740) were obtained from
American Type Culture Collection (ATCC, Rockville, MD,
USA), cultured in Roswell Park Memorial Institute (RPMI)-
1640 medium, and maintained at 37C under 5% CO2.
Human 293T embryonic kidney cells (CRL-11268) were
cultured in Dulbecco’s modified Eagle’s medium. Culture
media were supplemented with 10% fetal bovine serum,
2mM GlutaMAX-I (Invitrogen, Carlsbad, CA, USA), 100 U/mL
penicillin, and 100 mg/mL streptomycin. Normal prostate
epithelial cells (PrEC) were cultivated in PrEGM BulletKit
(Lonza, Basel, Switzerland) and maintained in accordance
with the manufacturer’s instructions.
2.3. Prediction of miR-204-5p target genes
Potential miR-204-5p targets were predicted by computer-
based programs as described in a previous study.15 The
autophagy-related genes (LC3A, LC3B, ATG7, and ATG12),
cell-cycle-related genes (CCND1 and CDK6), and anti-
apoptotic genes (IGF1R, BCL2, BCL2L1, BCL2L2m Mcl-1, and
BCL-xL) are listed as predicted targeting genes for has-miR-
204-5p in the TargetScan database. The secondary structure
and the binding energy between miR-204-5p and BCL2 or
between miR-204-5p and the BCL2L2 30-untranslated region
(UTR) duplex were generated by RNAhybrid software
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/).16
BCL2 mRNA sequences of human (NM_000633), chimpanzee
(XM_001145537), dog (NM_001002949), cat (NM_001009340),
rat (NM_016993), and mouse (NM_009741) were retrieved
from GenBank, and the alignment of these sequences was
performed using Clustal Omega (http://www.ebi.ac.uk/
Tools/msa/clustalo/).miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
16/j.asjsur.2016.07.001
Table 1 List of oligonucleotides and polymerase chain reaction primer pairs used in this study.
Name Sequences (50/30)
Oligonucleotides for construction of miRNA expression vectors
Has-miR-204 (Top) TGCTGTTCCCTTTGTCATCCTATGCCTGTTTTGGCCACTGACTGACAGGCATAGTGACAAAGGGAA
Has-miR-204 (Bot) CCTGTTCCCTTTGTCACTATGCCTGTCAGTCAGTGGCCAAAACAGGCATAGGATGACAAAGGGAAC
Has-miR-15 (Top) TGCTGTAGCAGCACATAATGGTTTGTGGTTTTGGCCACTGACTGACCACAAACCTATGTGCTGCTA
Has-miR-15 (Bot) CCTGTAGCAGCACATAGGTTTGTGGTCAGTCAGTGGCCAAAACCACAAACCATTATGTGCTGCTAC
Has-miR-214 (Top) TGCTGACAGCAGGCACAGACAGGCAGTGTTTTGGCCACTGACTGACACTGCCTGTGTGCCTGCTGT
Has-miR-214 (Bot) CCTGACAGCAGGCACACAGGCAGTGTCAGTCAGTGGCCAAAACACTGCCTGTCTGTGCCTGCTGTC
Stemeloop RT primers
miR-204 GTT GGC TCT GGT GCA GGG TCC GAG GTA TTC GCA CCA GAG CCA ACA GGC AT
SNORD43 GTT GGC TCT GGT GCA GGG TCC GAG GTA TTC GCA CCA GAG CCA ACA ATC AG
Oligonucleotides for miRNA QPCR
miR-204_F GGG TTC CCT TTG TCA TCC T
SNORD43_F GTG AAC TTA TTG ACG GGC G
Universal reverse primer GTG CAG GGT CCG AGG T
Probe for miRNA QPCR
UPL#21 /56-FAM/TþGþG þCþTþC þTG/3IABkFQ/
Oligonucleotides for reporter vector construction
pmiR-204PTS (Top) CTAGCAGGCATAGGATGACAAAGGGAAGATATCAGGCATAGGATGACAAAGGGAAC
pmiR-204PTS (Bot) TCGAGTTCCCTTTGTCATCCTATGCCTGATATCTTCCCTTTGTCATCCTATGCCTG
pmiR-204MTS (Top) CTAGCTTCCCTTTGTCATCCTATGCCTGATATCTTCCCTTTGTCATCCTATGCCTC
pmiR-204MTS (Bot) TCGAGAGGCATAGGATGACAAAGGGAAGATATCAGGCATAGGATGACAAAGGGAAG
pmiR-Bcl2-204TS (Top) TCGAGGCAAAACGTCGAATCAGCTATTTACTGCCAAAGGGAAATATCATTTATGC
pmiR-Bcl2-204TS (Bot) GGCCGCATAAATGATATTTCCCTTTGGCAGTAAATAGCTGATTCGACGTTTTGCC
pmiR-Bcl2-204MTS (Top) TCGAGGCAAAACGTCGAATCAGCTATTTACTGCC TTTCCCTT ATATCATTTATGC
pmiR-Bcl2-204MTS (Bot) GGCCGCATAAATGATATAAGGGAAAGGCAGTAAATAGCTGATTCGACGTTTTGCC
pmiR-15PTS (Top) CTAGCCACAAACCATTATGTGCTGCTAGATATCCACAAACCATTATGTGCTGCTAC
pmiR-15PTS (Bot) TCGAGTAGCAGCACATAATGGTTTGTGGATATCTAGCAGCACATAATGGTTTGTGG
pmiR-15MTS (Top) CTAGCTAGCAGCACATAATGGTTTGTGGATATCTAGCAGCACATAATGGTTTGTGC
pmiR-15MTS (Bot) TCGAGCACAAACCATTATGTGCTGCTAGATATCCACAAACCATTATGTGCTGCTAG
pmiR-Bcl2-15TS (Top) TCGAGAAGTGATGAATATGGAATATCCAATCCTG TGCTGCTA TCCTGCCAAAAGC
pmiR-Bcl2-15TS (Bot) GGCCGCTTTTGGCAGGATAGCAGCACAGGATTGGATATTCCATATTCATCACTTC
pmiR-Bcl2-15MTS (Top) TCGAGAAGTGATGAATATGGAATATCCAATCCTG TAGCAGCA TCCTGCCAAAAGC
pmiR-Bcl2-15MTS (Bot) GGCCGCTTTTGGCAGGATGCTGCTACAGGATTGGATATTCCATATTCATCACTTC
QPCR primers
HsBcl2-5QP1 CTGTGGTCCACCTGACCCTCCGC
HsBcl2-3QP1 CGTACAGTTCCACAAAGGCATCCCAGC
HsBcl2l2-5QP1 GAGCCATATAGTTCCTTGGGA
HsBcl2l2-3QP1 TAGAATAAGTGGGGAGTGGGA
HsMcl1-5QP1 CCACCGGCGCCAAGGACACAAAG
HsMcl1-3QP1 AGCATGCCTTGGAAGGCCGTCTCG
HsCCND1-5QP1 CGTTGTACCTGTAGGACTCT
HsCCND1-3QP1 TGGCTTCATTGAGATTTGGAG
Hs-CDK6-5QP1 AGCAAGAACCTTCCTACCTATT
Hs-CDK6-3QP1 TGAAGACAGTAGCCTTAGAGATAA
HS-ATG7-5QP1 GCTTGTTCTTCCAAAGTTCTTG
Hs-ATG7-3QP1 ATGGTCTCATCATCGCTCAT
Hs-ATG12-5QP1 CATTCTTTGAAGATGCCTTGTGTT
Hs-ATG12-3QP1 AGTGGTAGTTTGCTCTAAGTGTTT
Hs-LC3A-5QP1 CAGGTGCAAGGAGAAAGGAT
Hs-LC3A-3QP1 TGAGACAGTGTCAGAACTACC
Hs-BECN1-5QP1 CCAGAGCTACAACATGCCATC
Hs-BECN1-3QP1 TCAGAGAAGAAAGGGAAAGGAGTC
HsBad-5QP1 CATCATGGAGGCGCTGGGGC
HsBad-3QP1 TGCCGCATCTGCGTTGCTGTGCC
EGFP-5QP1 CGACGGCAACTACAAGAC
EGFP-3QP1 TAGTTGTACTCCAGCTTGTGC
miRNA targeting sites are underlined and miRNA seed sequences are boxed.
BotZ bottom; EGFPZ enhanced green fluorescent protein; miRNAZmicroRNA; MTSZmutated target site; PTSZ positive target site;
QPCR Z quantitative polymerase chain reaction; RT Z reverse transcription.
miR-204-5p targets BCL2 and induces apoptosis in prostate cancer cells 3
+ MODEL
Please cite this article in press as: Lin Y-C, et al., Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
cancer cells, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.07.001
4 Y.-C. Lin et al.
+ MODEL
Please cite this article in press as: Lin Y-C, et al., Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
cancer cells, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.07.001
miR-204-5p targets BCL2 and induces apoptosis in prostate cancer cells 5
+ MODEL2.4. Detection of miR-204-5p expression
We used a highly sensitive reverse transcriptaseepolymerase
chain reaction (RT-PCR) method to determine the expression
level of miR-204-5p in PrEC, Rv1, and PC3 cells using Moloney
murine leukemia virus RT (Epicentre) with stemeloop RT
primer specific for miR-204-5p or SNORD43 (internal con-
trol). Quantitative PCR (QPCR) to detect miR-204-5p or
SNORD43 was subsequently performed using miRNA-specific
forward primers, miRNA universal reverse primer, and an
UPL#21 probe. All oligonucleotides used in this study were
synthesized by IDT (Integrated DNATechnologies, Singapore)
and are listed in Table 1.
2.5. Real-time quantitative RT-PCR
Cells that reached approximately 70e80% confluences were
transfected in 10-cm dishes with pSM-204 using a polymer-
based transfection reagent (Transfec 293, GeneDireX, Tai-
pei, Taiwan). The expression level of miR-204-5p in trans-
fected cells was measured as described previously.17 To
detect the expression levels of BCL2, BCL2L2 (Bcl-w), MCL-
1, CCND1, CDK6, ATG7, ATG12, LC3A, BECN1, and BAD,
first-strand complementary DNA (cDNA) was synthesized
from total RNA (2 mg) using a first strand cDNA synthesis kit
(Thermo Scientific) and oligo(dT) primers. QPCR was per-
formed in a 20-mL reaction mixture that contained 0.5 mL of
cDNA and 1 KAPA SYBR FAST universal QPCR master mix
(Kapa Biosystems, Boston, MA, USA). Enhanced green fluo-
rescent protein (EGFP) coexpressed with miR-204-5p was
used as an internal standard to eliminate possible differ-
ences in transfection efficiency. The data were collected
from triplicate experiments that were repeated three times
using different batches of RNA samples. The data are
expressed as mean  standard deviation. The specific
primer pairs used are listed in Table 1.
2.6. BCL2 30-UTR reporter plasmid construction and
luciferase assays
Double-stranded oligonucleotides containing 19 bases up-
stream and 11 bases downstream of miR-204-5p or miR-15a
seed sequences of BCL2 30-UTRs were synthesized,
annealed, cloned downstream of the luciferase gene (NheI/
XhoI sites) in the pmirGLO vector (Promega, Madison, WI,
USA), and designated as “pmiR-Bcl2-204TS” and “pmiR-
Bcl2-15TS,” respectively. A similar cloning step using
reverse seed sequences of miR-204-5p and miR-15a on the
BCL2 30-UTR yielded “pmiR-Bcl2-204MTS” and “pmiR-Bcl2-
15MTS,” respectively, which served as negative controls.Figure 1 Downregulation of miR-204-5p in human prostate cance
expression of antiapoptotic genes. (A) miR-204-5p was downregulate
Enhanced expression of miR-204-5p in prostate cancer cells by trans
predicted miR-204-5p targeted genes in pSM-204-transfected Rv1
independent experiments and are expressed as the mean percen
(pSM). * p < 0.05. GAPDH Z glyceraldehyde 3-phosphate dehydrog
Please cite this article in press as: Lin Y-C, et al., Tumor suppressor
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antisense and sense sequences of miR-204-5p and miR-15a,
respectively, to generate positive target sites (PTSs) and
mutated target sites (MTSs) on the reporter vectors. The
293T cells were cotransfected with miR-204-5p (pSM-204),
miR-15a (pSM-15), or control (pSM) and reporter plasmids.
Firefly and Renilla luciferase activities were measured
consecutively at 24 hours post-transfection using a Promega
Dual-luciferase kit according to the manufacturer’s in-
structions. Relative protein levels were expressed as
firefly/Renilla luciferase ratios.2.7. Western blot analyses
Protein samples were collected at 96 hours post-
transfection using radioimmunoprecipitation assay buffer
containing 1 protease inhibitor cocktail. Protein concen-
trations were determined using a micro bicinchoninic acid
protein assay kit, and the subsequent Western blot analyses
were performed as described previously.15 Band signals
were acquired in the linear range of the scanner using
densitometric software (Totallab, Nonlinear Dynamics, NC,
USA). The ratio of BCL2 to EGFP band intensities was used
to quantitate BCL2 modulation by miR-204-5p.2.8. Cell viability and apoptosis detection
Cell viability was measured with WST-1 reagent. To detect
apoptosis, we evaluated cytochrome C release to the
cytosol and caspase 3/7 activity in transfected cells. The
protein fractions from cytosol were isolated using a mito-
chondria isolation kit (Thermo Scientific, MA, USA) and then
analyzed by Western blot using anticytochrome C antibody
and enhanced chemiluminescence as described earlier.
Caspase 3/7 activity was assayed using an EnzChek
Caspase-3 assay kit Number 2 (Invitrogen). Measured fluo-
rescence levels were normalized to the fluorescence levels
of nontransfected cell lysates, and caspase 3/7 activities
were normalized to cell viability.2.9. Statistical analysis
Data are presented as the means  standard deviation of
three independent experiments, each performed in tripli-
cate. Student t test was used to differentiate the statistical
significance. A value of p < 0.05 was considered statistically
significant.r cells, and enforced expression of miR-204-5p decreased the
d in prostate cancer cells compared with PrEC normal cells. (B)
fection of pSM-204. (C) Decreased expression level of multiple-
(left row) and PC3 (right row) cells. The data represent three
tage  standard deviation relative to the vector-only control
enase; mRNA Z messenger RNA.
miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
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To access the basal expression profile of miR-204-5p, we
compared the endogenous level of miR-204-5p in PrEC,
LNCaP, Rv1, and PC3 cells using a highly sensitive RT-QPCR
method.18 As shown in Figure 1A, the expression level of
miR-204-5p was downregulated in LNCaP, Rv1, and PC3 cells
compared with normal PrEC cells.3.2. Elevated level of miR-204-5p in pSM-204-
transfected cells
To study the effect of miR-204-5p on the expression of
putative targets in cancer cells, we increased the func-
tional level of miR-204-5p in PCa cells (PC3, Rv1, and
LNCaP). The embryonic kidney cells (293T) were included
as reference cancer cells. As expected, the expression level
of miR-204-5p was elevated in pSM-204-transfected cells
when compared with control. As shown in Figure 1B, miR-
204-5p transcripts were elevated to 5.62  0.50 folds,
5.41  0.51 folds, 4.22  0.35 folds, and 6.21  0.24 folds in
LNCaP, Rv1, PC3, and 293T cells, respectively.Figure 2 BCL2 is a predicted target of miR-204-5p. (A) Putative bi
as detected by several prediction databases. Those not listed in the
that contain the putative miR-204-5p target site are highly conserv
underlined. The listed partial BCL2 30-UTR sequences are from the f
(Fca); rat (Rno); and mouse (Mmu). (C) Predicted RNA duplex s
generated by RNAhybrid. UTR Z untranslated region.
Please cite this article in press as: Lin Y-C, et al., Tumor suppressor
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downregulated genes involved in autophagy, cell
cycle, and antiapoptosis
To investigate whether the expression of these predicted
targeting genes was altered by enforced expression of miR-
204-5p, the total RNA was isolated from Rv1 and PC3 cells
transfected with pSM or pSM-204. The expression level of
these mRNAs was then evaluated by subsequent QPCR. Our
results demonstrated that multiple genes were down-
regulated by enforced expression of miR-204-5p in both Rv1
and PC3 cells, including LC3A, ATG12, CCND1, IGF1R, BCL2,
BCL2L2, and Mcl-1 (Figure 1C). Nevertheless, several genes
such as LC3B, ATG7 BCL2L1, and Bcl-xL were only down-
regulated in PC3 cells.3.4. BCL2 was predicted as a target for miR-204-5p
An in silico strategy was used to identify putative miR-204-
5p targets that may contribute to tumorigenesis. The pre-
diction results and score from TargetScan are listed in
Figure 2A. The BCL2-like 2 (BCL2L2) gene has been
demonstrated to be an miR-204-5p target gene.19 There-
fore, we included the predicted results of miR-204-5p/
BCL2L2 as a reference. Conserved binding sites on the 30-nding sites of miR-204-5p in the BCL2 and BCL2L2 30-UTR regions
databases are indicated by a dash. (B) BCL2 30-UTR sequences
ed among vertebrate species. The miR-204-5p seed sequence is
ollowing species: human (Hsa); chimpanzee (Ptr); dog (Cfa); cat
tructure of miR-204-5p/BCL2 and miR-204-5p/BCL2L2 binding
miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
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chimpanzee, dog, cat, rat, and mouse (Figure 2B), were
retrieved from the TargetScan program. This observation
suggests that miR-204-5p targeting of BCL2 is preserved
during evolution. The free energies of miR-204-5p binding
to the BCL2 and BCL2L2 binding sites were calculated as
19.4 kcal/mol and 18.3 kcal/mol, respectively, using
RNAhybrid software. The calculated binding energy further
emphasized that the targeting sequence within the BCL2 30-
UTR likely binds to miR-204-5p. The predicted structures of
miR-204-5p binding to BCL2 and BCL2L2 are shown in
Figure 2C.
3.5. miR-204-5p interacts directly with the 30-UTR
of BCL2
To substantiate that miR-204-5p directly regulates BCL2
through binding to its 30-UTR targeting sequences, we
tested whether the pSM-derived vectors could generate
functionally mature miRNAs using luciferase reporterFigure 3 Effect of the putative miR-204-5p targeting site derive
tration of luciferase reporter constructs used in this study. Lucifera
expressing a sense strand of miR-204-5p and (B) the positive and ne
(C) the 30-UTR of BCL2 reporter vectors (TS and MTS). miR-15a with
The data are presented as the mean  standard deviation of thr
p < 0.05. MTS Z mutated target site; PTS Z positive target site;
Please cite this article in press as: Lin Y-C, et al., Tumor suppressor
cancer cells, Asian Journal of Surgery (2016), http://dx.doi.org/10.10assays. As illustrated in Figure 3A, luciferase reporter
constructs bearing the PTS or mutative targeting site were
constructed and designated as “pmiR-204-5pPTS” and
“pmiR-204-5pMTS,” respectively. In addition, to test
whether miR-204-5p interacts directly with the putative
targeting sequence on the 30-UTR of BCL2, “pmiR-Bcl2-
204TS” (bearing sequence from the 30-UTR of BCL2) and
“pmiR-Bcl2-204MTS” (bearing the same 30-UTR sequence as
pmiR-Bcl2-204TS except that the predicted miR-204-5p
targeting seed sequence being mutated) were con-
structed. miR-15a with demonstrated targeting of BCL2 was
used as a positive control.5 As shown in Figure 3B, lucif-
erase activities decreased significantly in cells cotrans-
fected with pSM-204 and pmiR-204-5pPTS. None of the
miRNA expression plasmids had a regulatory effect on the
pmirGLO reporter vector with the MTSs (Figure 3B). When
we replaced the reporter vectors with pmiR-Bcl2-204TS and
pmiR-Bcl2-15TS bearing the BCL2 target sequences of miR-
204-5p and miR-15a, respectively, the luciferase activities
decreased (Figure 3C). We cloned reporter vectors (pmiR-d from the BCL2 30-UTR on luciferase expression. (A) An illus-
se activity in 293T cells transiently cotransfected with pSM-204
gative control reporter vectors (PTS and MTS, respectively) or
demonstrated targeting of BCL2 was used as a positive control.
ee independent experiments, each performed in triplicate. *
UTR Z untranslated region.
miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
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reversed seed sequences of miR-204-5p and miR-15a on the
30-UTR of BCL2 as the MTSs. As expected, these mutants
completely abolished the interaction between miR-204-5p
and miR-15a with the 30-UTR of BCL2 (Figure 3C). These
results indicated that pSM-204 and pSM-15 generate func-
tional and mature miRNAs that directly interact with the 30-
UTR of BCL2.3.6. Decreased BCL2 mRNA and protein levels in
pSM-204-transfected cells
The BCL2 mRNA expression level in pSM-204-transfected
cells was measured by QPCR at 48 hours post-transfection.
The BCL2 mRNA expression levels were reduced by
38.52  7.12%, 42.00  8.12%, 35.01  5.54%, and
35.12  6.18% in LNCaP, Rv1, PC3, and 293T cells,Figure 4 BCL2 expression is repressed by miR-204-5p. (A) The r
were measured in cells transfected with pSM-204 and pSM-214 a
polymerase chain reaction at 48 hours post-transfection. As a valida
as a positive control. (B) Representative Western blot results of BC
pSM-204- and pSM-214-transfected cells. (C) The relative protein
were quantified. * p < 0.05. C-caspase Z cleaved caspase; EGFP Z
Please cite this article in press as: Lin Y-C, et al., Tumor suppressor
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(Figure 4A). As a positive control, the mRNA expression
levels of BCL2L2 were reduced in all cell lines tested. We
included miR-214, which has no detected target site in the
30-UTR of BCL2, as a negative control. Therefore, BCL2
expression was not altered by pSM-214 transfection
(Figure 4A). To confirm that miR-204-5p modulates the BCL2
system by specifically repressing BCL2 expression, we
analyzed the mRNA expression of MCL-1, another anti-
apoptotic BCL2 family member, and BAD, a proapoptotic
protein that interacts with BCL2, in miR-204-5p-transfected
cells. According to TargetScan, no predictive miR-204-5p
target sites are present in the 30-UTRs of MCL-1 and BAD.
Surprisingly, the MCL-1 expression levels decreased in
LNCaP and Rv1 cells transfected with pSM-204 (Figure 4A).
However, in PC3 and 293T cells, the MCL-1 level was not
altered by pSM-204 transfection. In addition, decreased
BAD levels were only detected in Rv1 cells transfected withelative messenger RNA (mRNA) levels of BCL2, Mcl-1, and Bad
nd compared with vector-only controls (pSM) by quantitative
ted miR-204-5p target, the mRNA level of BCL2L2 was measured
L2, MCL-1, BAD, BAX, and cleaved caspase 3 protein levels in
levels in each treatment from three independent experiments
enhanced green fluorescent protein.
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+ MODELpSM-204 (Figure 4A). Therefore, the decreased levels of
MCL-1 in LNCaP and Rv1 cells and BAD in Rv1 cells may be
cell-specific secondary effects after pSM-204 transfection.
Next, we examined the BCL2 protein level in response to
elevated miR-204-5p expression. As shown in Figure 4B, the
level of BCL2 decreased in pSM-204-transfected cells
compared with the vector-only control (Rv1,
32.26  10.21%; PC3, 35.72  10.17%; and 293T,
28.35  9.52%). These data suggest that miR-204-5p sup-
presses BCL2 expression at both RNA and protein levels.Figure 5 Repression of BCL2 by miR-204-5p reduces cell
viability and induces apoptosis. Cells were transfected with the3.7. BCL2 repression by miR-204-5p reduces cell
viability and induces apoptosis in PCa cells
As shown in Figure 5A, cell viabilities decreased in cells
transfected with pSM-204 (Rv1, 57.31  2.82%; 293T,
53.12  2.34%; and PC3, 59.13  7.18%) compared with the
vector-only control. To confirm that miR-204-5p is respon-
sible for the decreased cell viability observed with BCL2
targeting, a rescue experiment was performed in which
pSM-204 was cotransfected with reporter constructs that
harbor the positive miR-204-5p target sequences (pmiR-
204-5pPTS) or the 30-UTR of BCL2 (pmiR-Bcl2-204TS). These
two reporters generated miR-204-5p target sequences to
compete with exogenous miR-204-5p or endogenous BCL2
transcripts. As shown in Figure 5A, the cotransfection of
pSM-204 with pmiR-204-5pPTS restored cell viability in Rv1,
PC3, and 293T cells, whereas the cotransfection of pSM-204
with pmiR-Bcl2-204TS partially rescued cell viability in
these cells. These results indicate that miR-204-5p targets
BCL2 and leads to decreased cell viability; however, other
miR-204-5p mRNA targets may also contribute to lost
viability because the cell viability did not fully recover in
cells cotransfected with pmiR-Bcl2-204TS and pSM-204.
Furthermore, cell viability in cells treated with Z-VAD-
FMK, a pan-caspase inhibitor, prior to the pSM-204 trans-
fection was not reduced, suggesting that miR-204-5p-
caused cell death is mainly through the activation of the
caspase pathway. In Figure 5B, cytochrome C was released
to the cytosol in pSM-204-transfected Rv1 and PC3 cells,
indicating that miR-204 targeting of BCL2 causes an
imbalance of the antiapoptotic and proapoptotic protein
levels and induces the mitochondria-dependent apoptotic
pathway. Caspase 3/7 activation was detected in cells
transfected with pSM-204 and could be suppressed by
cotransfection with reporter constructs (Figure 5C).indicated vectors. At 72 hours post-transfection, (A) cell
viability, (B) cytosolic cytochrome C, and (C) caspase 3/7 ac-
tivity were detected. Reporter vectors expressing a positive
miR-204-5p target sequence (pmiR-204-5pPTS) or containing
the BCL2 30-UTR (pmiR-Bcl2-204TS) were cotransfected with
pSM-204 in the rescue experiments. Cells were pretreated with
10mM Z-VAD-FMK prior to the transfection. Enhanced green
fluorescent protein served as loading controls for cytosolic
proteins. * p < 0.05. UTR Z untranslated region.4. Discussion
The imbalance of antiapoptotic and proapoptotic proteins
plays an important role in cancer development and pro-
gression. BCL2 upregulation has been demonstrated in
many cancer types.18 BCL2 inhibits apoptosis by interacting
with proapoptotic members of the BCL2 family, such as
BAD, BAX, and BID. A decreased level of BCL2 disrupts the
balance of antiapoptotic and proapoptotic homodimers,
and thus, activates the apoptotic cascade.17 BCL2 is highly
expressed in androgen-independent PCa.20 Therefore, BCL2
has become an attractive therapeutic target of cancer
treatments.21Please cite this article in press as: Lin Y-C, et al., Tumor suppressor
cancer cells, Asian Journal of Surgery (2016), http://dx.doi.org/10.10miR-204-5p has been demonstrated to be involved in the
regulation of multiple functions in different cell types of
human. It was reported to target TGF-b receptor 2 and
SNAIL2 in retinal pigmented epithelium, which led to amiRNA-204-5p promotes apoptosis by targeting BCL2 in prostate
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+ MODELdecrease in transepithelial resistance.22 miR-204-5p has
also been found to be highly abundant in distal axons,
suggesting its potential role in neuronal growth and
development.23
Downregulation of miR-204-5p has been reported in
human breast cancer,24 bladder cancer,13,25 renal clear cell
carcinoma,26 head and neck tumor,27 leukemia,28 and
endometrioid adenocarcinoma.10 Here, we showed that
manipulation of miR-204-5p expression in PCa cells induces
apoptosis by directly targeting BCL2. These results indicate
that the interaction between miR-204-5p and BCL2 may be
universal. As a positive control, we also demonstrated that
another antiapoptotic protein, BCL2L2, was targeted by
miR-204-5p. Interestingly, MCL-1 expression levels were
altered in miR-204-5p-transfected LNCaP and Rv1 cells.
Because there is no predictive target site of miR-204-5p on
the 30-UTR of MCL-1, the decreased level of MCL-1 is likely
to be a secondary effect of miR-204-5p expression.
The expression of the proapoptotic gene BAD was not
affected by the elevated level of miR-204-5p in LNCaP, PC3,
and 293T cells, while decreased levels of BAD were detec-
ted in Rv1 cells. This observation is not consistent with the
common knowledge that BAD promotes apoptosis. The
decreased level of BAD observed in Rv1 cells is likely to be a
result of apoptosis induction by miR-204-5p because
apoptosis induction was detected in all tested cell lines.
The elevation of miR-204-5p expression significantly
reduced the cell viability of all transfected cancer cell
lines. Cell viabilities were restored fully or partially by the
cotransfection of reporter constructs bearing a positive
miR-204-5p target site (pmiR-204-5pPTS) or a BCL2 target
site (pmiR-Bcl2-204TS), respectively. These results indicate
that BCL2 is not the only target of miR-204-5p responsible
for the lost cell viability. Indeed, as mentioned earlier,
BCL2L2 was reported to be an antiapoptotic target of miR-
204-5p in human trabecular meshwork (HTM) cells. The
elevation of miR-204-5p in HTM cell lines also induced
apoptosis and caused cell death.19 This finding further
supports the idea that miR-204-5p functions as a tumor-
suppressing miRNA by targeting antiapoptotic genes.
The limitation of the study is that it was a cell-based
study. Hence, future studies using clinical samples directed
toward the elucidation of the relationship between miR-
204-5p and antiapoptotic genes may provide further insights
into the design of novel molecular therapies for PCa and,
more importantly, into the inhibition of cancer progression.5. Conclusion
Our results showed that BCL2 is a direct target of miR-204-
5p in human PCa cells. miR-204-5p overexpression resulted
in the decreased level of BCL2, which in turn increased
apoptosis and decreased cellular viability. Taken together,
miR-204-5p can be a possible novel molecular therapeutic
candidate for PCa.Acknowledgments
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